MCID: PYL005
MIFTS: 57

Pyelonephritis

Categories: Nephrological diseases

Aliases & Classifications for Pyelonephritis

Summaries for Pyelonephritis

MalaCards based summary : Pyelonephritis is related to pyelitis and acute cystitis. An important gene associated with Pyelonephritis is TLR4 (Toll Like Receptor 4), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs leucovorin and Nitrofurantoin have been mentioned in the context of this disorder. Affiliated tissues include kidney, testes and prostate, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Wikipedia : 77 Pyelonephritis is inflammation of the kidney, typically due to a bacterial infection. Symptoms most... more...

Related Diseases for Pyelonephritis

Diseases in the Pyelonephritis family:

Chronic Pyelonephritis Acute Pyelonephritis

Diseases related to Pyelonephritis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 547)
# Related Disease Score Top Affiliating Genes
1 pyelitis 32.2 CRP CXCL8 CXCR1 IL6 TLR4
2 acute cystitis 32.2 ALB CCL2 CRP CXCL8 IL6
3 acute pyelonephritis 32.1 ALB CRP CXCL8 CXCR1 CXCR2 IL10
4 cystitis 31.5 CCL2 CRP CXCL8 IL6 TLR4 TNF
5 hydronephrosis 31.0 ALB CCL2 NAGLU
6 fasciitis 30.6 CXCL8 IL6 TNF
7 pyuria 30.5 ALB CRP CXCL8
8 septic arthritis 30.3 CRP CXCL8 TLR4
9 spinal cord injury 30.2 CXCL8 IL6 TNF
10 haemophilus influenzae 30.2 CXCL8 IL1B TNF
11 interstitial nephritis 30.1 ACE ALB CRP UMOD
12 infective endocarditis 30.0 CRP IL6 TNF
13 purpura 30.0 CRP IL6 TNF
14 spondylitis 30.0 CRP IL6 TNF
15 acute kidney tubular necrosis 30.0 ALB NAGLU UMOD
16 endometriosis 29.9 CCL2 CXCL8 IL1B IL6
17 bacteriuria 29.9 CCL2 CXCL8 CXCR1 CXCR2 IL6 TLR4
18 cerebral palsy 29.9 IL1B IL6 TNF
19 salmonellosis 29.8 ALB IL1B TLR4
20 interstitial cystitis 29.8 CXCL8 IL6 UMOD
21 diabetes mellitus 29.8 ACE ALB CRP IL1B IL6 TNF
22 acute pancreatitis 29.8 CRP CXCL8 IL10 IL6
23 posterior urethral valves 29.7 ACE IL6 TNF
24 urinary tract obstruction 29.7 ALB CCL2 NAGLU UMOD
25 prostatitis 29.7 CXCL8 IL10 IL1B IL6 TNF
26 eclampsia 29.7 ALB PGF TNF
27 aspergillosis 29.6 IL10 TLR4 TNF
28 endocarditis 29.6 ALB CRP CXCL8 IL10 IL6 TNF
29 encephalitis 29.5 CCL2 CCL5 IL1B
30 osteomyelitis 29.5 CXCL8 IL10 IL1B IL6 TNF
31 respiratory failure 29.4 ACE ALB CRP CXCL8 TNF
32 obstructive jaundice 29.4 ALB CRP CXCL8 IL6 TNF
33 kidney disease 29.4 ACE ALB CCL2 CRP IL6 NAGLU
34 adult respiratory distress syndrome 29.4 ACE CXCL8 IL10 IL6 TNF
35 chronic kidney failure 29.3 ACE ALB CRP IL6 UMOD
36 colitis 29.3 CXCL8 IL10 IL1B IL6 TLR4 TNF
37 end stage renal failure 29.3 ACE ALB CRP IL6 TNF UMOD
38 bronchitis 29.2 ALB CRP CXCL8 TNF
39 melioidosis 29.2 IL10 IL6 TLR4 TNF
40 arthritis 29.2 CCL2 CXCL8 IL10 IL1B IL6 TNF
41 iga glomerulonephritis 29.2 ACE ALB CCL2 IL6 NAGLU
42 cholangitis 29.2 ALB CRP IL6 TNF
43 myeloma, multiple 29.1 ALB CRP CXCL8 IL6 TNF
44 appendicitis 29.0 ALB CRP CXCL8 IL10 IL1B IL6
45 brucellosis 28.9 CRP CXCL8 IL10 IL6 TLR4 TNF
46 meningitis 28.9 ALB CCL2 CRP CXCL8 IL10 IL1B
47 kawasaki disease 28.8 ALB CCL2 CRP IL10 IL6 TNF
48 arteriosclerosis 28.7 ACE CCL2 CRP IL10 IL6 TLR4
49 chlamydia 28.6 CRP CXCL8 IL10 IL1B IL6 TLR4
50 ulcerative colitis 28.6 CRP CXCL8 IL10 IL1B IL6 TLR4

Comorbidity relations with Pyelonephritis via Phenotypic Disease Network (PDN): (show all 22)


Active Peptic Ulcer Disease Acute Cystitis
Acute Kidney Failure Alzheimer Disease
Chronic Kidney Failure Chronic Myocardial Ischemia
Cystitis Decubitus Ulcer
Deficiency Anemia Esophagitis
Heart Disease Hydronephrosis
Hypertension, Essential Hypothyroidism
Iron Deficiency Anemia Kidney Disease
Nephrolithiasis, X-Linked Recessive, with Renal Failure Osteoporosis
Paralytic Ileus Protein-Energy Malnutrition
Schizophreniform Disorder Ureterolithiasis

Graphical network of the top 20 diseases related to Pyelonephritis:



Diseases related to Pyelonephritis

Symptoms & Phenotypes for Pyelonephritis

GenomeRNAi Phenotypes related to Pyelonephritis according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.4 ACE CXCL8 IL10 IL1B TNF UMOD
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.4 ACE CXCL8 IL10 IL1B TNF UMOD

MGI Mouse Phenotypes related to Pyelonephritis:

47 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 10.21 ACE CCL2 CCL5 CRP CXCR1 CXCR2
2 cardiovascular system MP:0005385 10.18 ACE CRP CXCR2 IL10 IL1B IL6
3 growth/size/body region MP:0005378 10.16 ACE CXCR2 IL10 IL1B IL6 NAGLU
4 homeostasis/metabolism MP:0005376 10.14 ACE ALB CRP CXCR2 IL10 IL1B
5 hematopoietic system MP:0005397 10.13 ACE CCL5 CXCR1 CXCR2 IL10 IL1B
6 adipose tissue MP:0005375 9.97 ACE IL6 PGF TLR4 TNF UMOD
7 liver/biliary system MP:0005370 9.92 ACE ALB CXCR2 IL10 IL6 NAGLU
8 neoplasm MP:0002006 9.91 ACE ALB CXCR2 IL10 IL1B IL6
9 renal/urinary system MP:0005367 9.7 ACE ALB CXCR2 IL6 NAGLU TLR4
10 skeleton MP:0005390 9.56 CXCR2 IL10 IL1B IL6 NAGLU TLR4
11 vision/eye MP:0005391 9.17 CXCR2 IL10 IL6 NAGLU PGF TLR4

Drugs & Therapeutics for Pyelonephritis

Drugs for Pyelonephritis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 178)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
leucovorin Approved Phase 4,Phase 3,Not Applicable 58-05-9 6006 143
2
Nitrofurantoin Approved, Vet_approved Phase 4,Phase 3,Not Applicable 67-20-9 5353830
3
Trimethoprim Approved, Vet_approved Phase 4,Phase 3,Not Applicable 738-70-5 5578
4
Sulfamethoxazole Approved Phase 4,Phase 3,Not Applicable 723-46-6 5329
5
Amoxicillin Approved, Vet_approved Phase 4,Phase 3,Not Applicable 26787-78-0 33613
6
Cephalexin Approved, Investigational, Vet_approved Phase 4,Not Applicable 15686-71-2 27447
7
Cefuroxime Approved Phase 4,Not Applicable 55268-75-2 5361202 5479529
8
Clavulanate Approved, Vet_approved Phase 4,Phase 3,Not Applicable 58001-44-8 5280980
9
Cefixime Approved, Investigational Phase 4,Phase 1 79350-37-1 5362065 54362
10
Ceftriaxone Approved Phase 4,Phase 3 73384-59-5 5479530 5361919
11
Ofloxacin Approved Phase 4,Phase 3,Phase 2 82419-36-1 4583
12
Levofloxacin Approved, Investigational Phase 4,Phase 3,Phase 2 100986-85-4 149096
13
Ciprofloxacin Approved, Investigational Phase 4,Phase 3,Phase 2 85721-33-1 2764
14
Ibuprofen Approved Phase 4 15687-27-1 3672
15
Fosfomycin Approved Phase 4,Phase 2,Phase 3,Phase 1 23155-02-4 446987
16
Cilastatin Approved, Investigational Phase 4,Phase 2 82009-34-5 6435415 5280454
17
Imipenem Approved Phase 4,Phase 3,Phase 2 74431-23-5, 64221-86-9 104838
18
Azithromycin Approved Phase 4,Phase 3 83905-01-5 55185 447043
19
Metronidazole Approved Phase 4 443-48-1 4173
20
Acetaminophen Approved Phase 4 103-90-2 1983
21
Ketoprofen Approved, Vet_approved Phase 4 22071-15-4 3825
22
Cefoxitin Approved Phase 4,Not Applicable 35607-66-0 441199
23
Cefotaxime Approved Phase 4,Not Applicable 63527-52-6 456256 5742673
24
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Not Applicable 59-30-3 6037
25 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
26 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
27 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
28 Antitubercular Agents Phase 4,Phase 3,Not Applicable
29 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
30 Anti-Infective Agents, Urinary Phase 4,Phase 3,Phase 2,Not Applicable
31 Fluoroquinolones Phase 4,Phase 2
32 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 2
33 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
34 Renal Agents Phase 4,Phase 3,Phase 2,Not Applicable
35 Antiprotozoal Agents Phase 4,Phase 3,Not Applicable
36 Folic Acid Antagonists Phase 4,Phase 3,Not Applicable
37 Vitamin B9 Phase 4,Phase 3,Not Applicable
38 Folate Phase 4,Phase 3,Not Applicable
39 Antiparasitic Agents Phase 4,Phase 3,Not Applicable
40 Antimalarials Phase 4,Phase 3,Not Applicable
41 Trimethoprim, Sulfamethoxazole Drug Combination Phase 4,Phase 3,Not Applicable
42 Vitamin B Complex Phase 4,Phase 3,Not Applicable
43 Analgesics Phase 4,Phase 1,Phase 2
44 Analgesics, Non-Narcotic Phase 4,Phase 1,Phase 2
45 Antirheumatic Agents Phase 4,Phase 1,Phase 2
46 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 1,Phase 2
47 Anti-Inflammatory Agents Phase 4,Phase 1,Phase 2
48 Peripheral Nervous System Agents Phase 4,Phase 1,Phase 2
49 cefuroxime axetil Phase 4,Not Applicable
50 beta-Lactamase Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable

Interventional clinical trials:

(show top 50) (show all 132)
# Name Status NCT ID Phase Drugs
1 Efficacy and Safety Study of Short-term Antibiotic for Pyelonephritis in Women Completed NCT01390623 Phase 4 Ceftriaxone
2 Treatment of Acute Pyelonephritis With Gram Negative Strains in Infants and Children Less Than 3 Years Old Completed NCT00136656 Phase 4 antibiotic;antibiotics
3 Treatment's Duration of Acute Uncomplicated Pyelonephritis Completed NCT00873626 Phase 4 levofloxacin, ciprofloxacin and ofloxacin (fluoroquinolones)
4 A Randomized Controlled Trial on Antibiotic Prophylaxis in Children With Vesico-Ureteral Reflux Completed NCT00382343 Phase 4 Sulfamethoxazole/trimethoprim
5 Pharmacokinetics of Ciprofloxacin in Pediatric Patients Completed NCT02598362 Phase 4 ciprofloxacin
6 Impact of Six Patient Information Leaflets (PIL) on Doctor Patient Communication Completed NCT02246361 Phase 4
7 Febrile Urinary Tract Infection Randomized Short Treatment Trial Completed NCT00809913 Phase 4 short treatment (ciprofloxacin)
8 Study To Evaluate The Efficacy And Safety Of Ciprofloxacin Extended-Release (Cipro® XR) 1000 mg Tablets Given Once Daily For 7 To 14 Days In The Treatment Of Patients 18 Years Or Older With Complicated Urinary Tract Infections Caused By Pseudomonas Aeruginosa And Other Common Uropathogens Completed NCT00481689 Phase 4 Cipro XR (Ciprofloxacin, BAYQ3939)
9 Study of Tomography of Nephrolithiasis Evaluation Completed NCT01451931 Phase 4
10 Ibuprofen Versus Mecillinam for Uncomplicated Cystitis Completed NCT01849926 Phase 4 Ibuprofen;Mecillinam
11 Impact on the Intestinal Microbiota of Treatment With Ceftriaxone in Women's Acute Community Pyelonephritis Recruiting NCT03179384 Phase 4 Ceftriaxone
12 Treating Pyelonephritis an Urosepsis With Pivmecillinam Recruiting NCT03282006 Phase 4 pivmecillinam
13 Management of Sub-Clinical Bacteriuria in Pregnancy Recruiting NCT03275623 Phase 4 Antibiotic
14 Antibiotic Prophylaxis Before Shock Wave Lithotripsy Recruiting NCT03692715 Phase 4 Ciprofloxacin;Placebo
15 Antibiotic Prophlaxis for High-risk Laboring Women in Low Income Countries Recruiting NCT03248297 Phase 4 Azithromycin;Azithromycin and amoxicillin;Placebo
16 Reducing Antibiotic Use for Uncomplicated Urinary Tract Infection in General Practice by Treatment With Uva Ursi (UU)- a Comparative Effectiveness Trial Recruiting NCT03151603 Phase 4 Arctuvan;Fosfomycin;Placebo to Arctuvan;Placebo to Fosfomycin
17 Cotrimoxazole Prophylaxis in Transurethral Resection or Greenlight Laser Vaporisation of the Prostate Recruiting NCT03633643 Phase 4 oral applications of TMP/SMX 800/160 mg (Nopil forte® tablets);oral applications of Placebo
18 The Bacteriuria in Renal Transplantation (BiRT) Study: A Trial Comparing Antibiotics Versus no Treatment in the Prevention of Symptomatic Urinary Tract Infection in Kidney Transplant Recipients With Asymptomatic Bacteriuria Recruiting NCT01871753 Phase 4
19 Prophylaxis of Ileostomy Closure Site Hernia by Placing Mesh Recruiting NCT02226887 Phase 4
20 Parenteral Antibiotics Compared to Combination of Oral and Parenteral Antibiotics in Colorectal Surgery Prophylaxis Recruiting NCT02505581 Phase 4 Extra dosage - cefuroxime (750mg) I.V;Cefuroxime 750mg oral;Metronidazole 250mg oral;Metronidazole 1,5gr Intravenous;Cefuroxime 1g Intravenous
21 Culture-guided Antimicrobial Prophylaxis in Men Undergoing Prostate Biopsy. Not yet recruiting NCT03228108 Phase 4 Ciprofloxacin;Trimethoprim/Sulfamethoxazole;Fosfomycin;Pivmecillinam/augmentin
22 Intravenous Paracetamol Versus Ketoprofen When Treating Renal Colic in Emergency Situations Suspended NCT01685658 Phase 4 Intravenous ketoprofen;Intravenous paracetamol
23 Safety and Efficacy Study of the Treatment of Kidney Infections With Short Course Levofloxacin Terminated NCT00239161 Phase 4 Levofloxacin
24 Evaluation of the Non-inferiority of Cefoxitin Versus Imipenem/Cilastatin in the Treatment of Urinary Tract Infections Caused by ESBL-producing Escherichia Coli Terminated NCT02474706 Phase 4 Cefoxitin;imipenem
25 L-carnitine on the Prevention of Renal Scarring in Acute Pyelonephritis Unknown status NCT02007889 Phase 3 L-carnitine
26 Oral Omega-3 for Reduction of Kidney Scar Due to Pyelonephritis in Children Unknown status NCT02192580 Phase 3 Omega-3
27 Doripenem in the Treatment of Complicated Lower Urinary Tract Infection or Pyelonephritis Completed NCT00210990 Phase 3 doripenem
28 Doripenem in the Treatment of Complicated Lower Urinary Tract Infection or Pyelonephritis Completed NCT00229021 Phase 3 doripenum
29 Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Levofloxacin in Complicated Urinary Tract Infection, Including Pyelonephritis Completed NCT01345929 Phase 3 CXA-201;Levofloxacin
30 A Comparison of the Effectiveness and Safety of Levofloxacin to That of Ciprofloxacin in Treating Complicated Urinary Tract Infection and Acute Pyelonephritis. Completed NCT00210886 Phase 3 levofloxacin
31 Study of Ceftolozane/Tazobactam (MK-7625A) in Japanese Participants With Uncomplicated Pyelonephritis and Complicated Urinary Tract Infection (MK-7625A-014) Completed NCT02728089 Phase 3 MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g)
32 Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections) Completed NCT01599806 Phase 3 Ceftazidime - Avibactam ( CAZ-AVI);Doripenem;Either switch to oral therapy: 500 mg of Ciprofloxacin (oral);or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)
33 Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections) Completed NCT01595438 Phase 3 Ceftazidime - Avibactam ( CAZ-AVI);Doripenem;Either switch to oral therapy: 500 mg of Ciprofloxacin (oral);or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)
34 A Study of Plazomicin Compared With Meropenem for the Treatment of Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis (AP) Completed NCT02486627 Phase 3 plazomicin;meropenem;levofloxacin (oral)
35 Efficacy/Safety of Meropenem-Vaborbactam Compared to Piperacillin-Tazobactam in Adults With cUTI and AP Completed NCT02166476 Phase 3 Meropenem-Vaborbactam;Piperacillin-Tazobactam;Levofloxacin;Saline
36 CSE-1034 (Ceftriaxone+ Sulbactam+ EDTA) Compared to Meropenem in Complicated Urinary Tract Infections (cUTIs) Caused by ESBL Producing Gram Negative Bacteria Completed NCT03477422 Phase 3 CSE-1034 (Ceftriaxone + Sulbactam + EDTA);Meropenem
37 Safety and Efficacy of ZTI-01 (IV Fosfomycin) vs Piperacillin/Tazobactam for Treatment cUTI/AP Infections Completed NCT02753946 Phase 2, Phase 3 ZTI-01;Piperacillin-tazobactam
38 A Study of Plazomicin Compared With Colistin in Patients With Infection Due to Carbapenem-Resistant Enterobacteriaceae (CRE) Completed NCT01970371 Phase 3 plazomicin;colistin;meropenem;tigecycline;antibiotic of Investigator's choice
39 Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults Completed NCT02168946 Phase 3 Vabomere;Best Available Therapy
40 A 28 - 90 Days Study to Evaluate the Safety, Tolerability, and Efficacy of Caspofungin Injection as Empirical Therapy in Indian Adults With Persistent Fever and Neutropenia (0991-053)(COMPLETED) Completed NCT00379964 Phase 3 caspofungin acetate
41 A Study to Assess the Safety, Tolerability and Efficacy of Ertapenem Sodium in the Treatment of Complicated Urinary Tract Infections (0826-048) Completed NCT00379951 Phase 3 ertapenem sodium
42 A Study of the Safety and Effectiveness of Oral Levofloxacin Compared With Oral Ciprofloxacin in the Treatment of Complicated Urinary Tract Infections Completed NCT00258089 Phase 3 Levofloxacin
43 Queen's University Investigation of Calcification in Chronic Kidney Disease Completed NCT00687661 Phase 3 Bisphosphonate;Placebo
44 Early Antiretroviral Treatment and/or Early Isoniazid Prophylaxis Against Tuberculosis in HIV-infected Adults (ANRS 12136 TEMPRANO) Completed NCT00495651 Phase 3 Antiretroviral medications;Antiretroviral medications+Isoniazid prophylaxis;Antiretroviral medications;Antiretroviral medications+Isoniazid prophylaxis
45 Safety and Efficacy Study of Cefepime-AAI101 in the Treatment of Complicated Urinary Tract Infections Recruiting NCT03687255 Phase 3 cefepime/AAI101 combination;Piperacillin/tazobactam
46 Evaluation of the Efficiency of Autologous Adipocytes Graft in Endoscopic Treatment in Vesico-Renal Reflux in Children Recruiting NCT00367159 Phase 3
47 Temocillin Versus a Carbapenem as Initial Intravenous Treatment for ESBL Related Urinary Tract Infections Recruiting NCT03543436 Phase 3 Temocillin;meropenem or imipenem
48 Study to Assess the Efficacy, Safety and Pharmacokinetics of Orally Administered Tebipenem Pivoxil Hydrobromide (SPR994) Compared to Intravenous Ertapenem in Patients With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) Not yet recruiting NCT03788967 Phase 3 Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr);Ertapenem
49 Study of Cefepime-tazobactam (FEP-TAZ) in Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP) Not yet recruiting NCT03630081 Phase 3 FEP-TAZ 4 g;Meropenem;ciprofloxacin 500 mg Optional Oral Switch
50 Safety and Efficacy Study of Cefepime/VNRX-5133 in Patients With Complicated Urinary Tract Infections Not yet recruiting NCT03840148 Phase 3 Cefepime/VNRX-5133;Meropenem

Search NIH Clinical Center for Pyelonephritis

Cochrane evidence based reviews: pyelonephritis

Genetic Tests for Pyelonephritis

Genetic tests related to Pyelonephritis:

# Genetic test Affiliating Genes
1 Pyelonephritis 30

Anatomical Context for Pyelonephritis

MalaCards organs/tissues related to Pyelonephritis:

42
Kidney, Testes, Prostate, Neutrophil, Bone, Colon, Spinal Cord

Publications for Pyelonephritis

Articles related to Pyelonephritis:

(show top 50) (show all 3241)
# Title Authors Year
1
Remarkable improvement in progressive multifocal leukoencephalopathy following acute pyelonephritis with bacteremia. ( 30612916 )
2019
2
Oral sitafloxacin vs intravenous ceftriaxone followed by oral cefdinir for acute pyelonephritis and complicated urinary tract infection: a randomized controlled trial. ( 30662274 )
2019
3
Vitamin A supplementation is effective for improving the clinical symptoms of urinary tract infections and reducing renal scarring in girls with acute pyelonephritis: a randomized, double-blind placebo-controlled, clinical trial study. ( 30670279 )
2019
4
Imaging in Acute Pyelonephritis: Utilization, Findings, and Effect on Management. ( 30708379 )
2019
5
The Use of Mobile Educational Tools to Improve Antimicrobial Prescription for the Treatment of Acute Pyelonephritis in Pregnancy: A Retrospective Cross-sectional Study. ( 30786306 )
2019
6
Urinary excretion of pentraxin-3 correlates with the presence of renal scar following acute pyelonephritis in children. ( 30796728 )
2019
7
Quick Sequential (Sepsis Related) Organ Failure Assessment: A high performance rapid prognostication tool in patients having acute pyelonephritis with upper urinary tract calculi. ( 30838345 )
2019
8
Serum alkaline phosphatase and γ-glutamyl transferase in acute pyelonephritis. ( 30841691 )
2019
9
Fosfomycin for injection (ZTI-01) vs Piperacillin-Tazobactam (PIP-TAZ) for the Treatment of Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis (AP): ZEUS, A Phase 2/3 Randomized Trial. ( 30861061 )
2019
10
Inappropriate empirical antibiotic therapy does not adversely affect the clinical outcomes of patients with acute pyelonephritis caused by extended-spectrum β-lactamase-producing Enterobacteriales. ( 30868326 )
2019
11
Polyarteritis nodosa presenting atypically as appendicitis and pyelonephritis in a single patient. ( 30709887 )
2019
12
Virulence factors and antimicrobial resistance in uropathogenic Escherichiacoli strains isolated from cystitis and pyelonephritis ( 30761847 )
2019
13
Host and Bacterial Markers that Differ in Children with Cystitis and Pyelonephritis. ( 30905425 )
2019
14
Cefmetazole for ESBL-producing Enterobacteriaceae in Pediatric Pyelonephritis. ( 30908807 )
2019
15
The pathogenesis and management of renal scarring in children with vesicoureteric reflux and pyelonephritis. ( 30847554 )
2019
16
Bilateral acute non-obstructive pyelonephritis presenting as acute kidney injury requiring haemodialysis. ( 30796082 )
2019
17
Concealed diagnosis of duodenal perforation in a patient with emphysematous pyelonephritis: the dilemma of air in the right perirenal space. ( 30765455 )
2019
18
Efficacy of intravesical targeting of novel quorum sensing inhibitor nanoparticles against Pseudomonas aeruginosa biofilm-associated murine pyelonephritis. ( 30741037 )
2019
19
Emphysematous Pyelonephritis Following Ureterovesical Reimplantation for Congenital Obstructive Megaureter. Pediatric Case Report and Review of the Literature. ( 30733936 )
2019
20
Temocillin breakpoints in pyelonephritis: evaluation in a murine model due to ESBL-producing Escherichia coli clinical isolates. ( 30689887 )
2019
21
The use of initial dosing of gentamicin in the management of pyelonephritis/urosepsis: A retrospective study. ( 30673763 )
2019
22
Neutrophil:Lymphocyte Ratio as a Predictive Factor for Success of Nephron-Sparing Procedures in Patients with Emphysematous Pyelonephritis. ( 30624199 )
2019
23
Re: The Clinical Impact of Bacteremia on Outcomes in Elderly Patients with Pyelonephritis or Urinary Sepsis: A Prospective Multicenter Study. ( 30577334 )
2019
24
Efficacy and Safety of Plazomicin Compared with Levofloxacin in the Treatment of Complicated Urinary Tract Infection and Acute Pyelonephritis: A Multicenter, Randomized, Double-Blind, Phase 2 Study. ( 29378708 )
2018
25
Risk Factors for Uroseptic Shock in Patients with Urolithiasis-Related Acute Pyelonephritis. ( 29065405 )
2018
26
Laparoscopic Heminephrectomy of Chronically Obstructed Horseshoe Kidney Moiety with Staghorn Calculus, Massive Pyonephrosis, and Xanthogranulomatous Pyelonephritis. ( 29662958 )
2018
27
Diffusion tensor imaging in acute pyelonephritis in children. ( 29789888 )
2018
28
Acute Pyelonephritis in Adults. ( 29565517 )
2018
29
Xanthogranulomatous pyelonephritis complicating crizotinib treatment of an ALK-rearranged non-small-cell lung cancer. ( 29472032 )
2018
30
Outcome of children with ESBL-E. coli acute pyelonephritis treated with cephalosporins. ( 29746942 )
2018
31
Extensive renal sinus lipomatosis in xanthogranulomatous pyelonephritis simulating liposarcoma. ( 29522292 )
2018
32
Emphysematous pyelonephritis and cystitis: A case report and literature review. ( 29916283 )
2018
33
Pyelonephritis in Dogs: Retrospective Study of 47 Histologically Diagnosed Cases (2005-2015). ( 29197113 )
2018
34
Reply: Is Taking Blood Cultures Indicated in Acute Pyelonephritis Patients Who Have Used Antibiotics before Presentation? ( 29637754 )
2018
35
Acute Pyelonephritis in Adults. ( 29298155 )
2018
36
Delayed diagnosis of xanthogranulomatous pyelonephritis in a quadriplegic patient with uncontrolled cutaneous fistula: A case report. ( 29480882 )
2018
37
D-dimer as a marker of acute pyelonephritis in infants younger than 24A months with urinary tract infection. ( 29306986 )
2018
38
Xanthogranulomatous Pyelonephritis. ( 29514028 )
2018
39
Pyeloduodenal fistula complicating xanthogranulomatous pyelonephritis. ( 29785659 )
2018
40
Useful Predictive Factors for Bacteremia among Outpatients with Pyelonephritis. ( 29321419 )
2018
41
Xanthogranulomatous pyelonephritis: A case report. ( 29888197 )
2018
42
Phylogenetic relationships, biofilm formation, motility, antibiotic resistance and extended virulence genotypes among Escherichia coli strains from women with community-onset primitive acute pyelonephritis. ( 29758033 )
2018
43
Re. "Diffusion weighted magnetic resonance imaging is more sensitive than dimercaptosuccinic acid scintigraphy in detecting parenchymal lesions in children with acute pyelonephritis: AA prospective study". ( 29778699 )
2018
44
Emphysematous pyelonephritis. ( 29445494 )
2018
45
Nephron-sparing management of Xanthogranulomatous pyelonephritis presenting as spontaneous renal hemorrhage: a case report and literature review. ( 29866085 )
2018
46
Diffusion-weighted magnetic resonance imaging is more sensitive than dimercaptosuccinic acid scintigraphy in detecting parenchymal lesions in children with acute pyelonephritis: AA prospective study. ( 29588142 )
2018
47
Is Taking Blood Cultures Indicated in Acute Pyelonephritis Patients Who Have Used Antibiotics before Presentation? ( 29637753 )
2018
48
Focal Xanthogranulomatous Pyelonephritis with Pulmonary Lesions on the Background of Type Two Diabetes Mellitus. ( 29666742 )
2018
49
Characterization of the Macrophage Infiltrate in a Case of Xanthogranulomatous Pyelonephritis. ( 29770220 )
2018
50
The clinical impact of bacteremia on outcomes in elderly patients with pyelonephritis or urinary sepsis: A prospective multicenter study. ( 29364923 )
2018

Variations for Pyelonephritis

Expression for Pyelonephritis

Search GEO for disease gene expression data for Pyelonephritis.

Pathways for Pyelonephritis

Pathways related to Pyelonephritis according to GeneCards Suite gene sharing:

(show top 50) (show all 73)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.05 CCL2 CCL5 CRP CXCL8 CXCR1 CXCR2
2
Show member pathways
13.88 CCL2 CCL5 CXCL8 CXCR1 CXCR2 IL10
3
Show member pathways
13.71 CCL2 CCL5 CXCL8 CXCR1 CXCR2 IL10
4
Show member pathways
13.56 CCL2 CCL5 CXCL8 IL10 IL1B IL6
5
Show member pathways
13.39 CCL2 CCL5 CXCL8 IL10 IL1B IL6
6
Show member pathways
13.38 CCL2 CCL5 CXCL8 CXCR1 CXCR2 IL10
7
Show member pathways
13.32 CCL2 CCL5 CXCL8 CXCR1 CXCR2 IL10
8
Show member pathways
13.22 ACE CCL2 CCL5 CXCL8 IL10 IL1B
9
Show member pathways
13.01 CCL2 CCL5 CXCL8 CXCR2 IL1B IL6
10
Show member pathways
12.89 CCL2 CCL5 CXCL8 CXCR1 CXCR2
11
Show member pathways
12.88 CXCL8 IL10 IL1B IL6 TNF
12
Show member pathways
12.82 CCL5 CXCL8 IL1B IL6 TLR4 TNF
13
Show member pathways
12.74 IL1B IL6 PGF TLR4 TNF
14
Show member pathways
12.65 IL10 IL1B IL6 TLR4 TNF
15
Show member pathways
12.65 CCL2 CCL5 CXCL8 IL1B IL6 TLR4
16
Show member pathways
12.64 CCL2 IL10 IL1B IL6 TNF
17 12.62 CCL2 CCL5 IL10 IL1B TNF
18
Show member pathways
12.49 CCL5 CXCL8 CXCR1 CXCR2
19
Show member pathways
12.44 IL10 IL1B IL6 TNF
20
Show member pathways
12.41 CCL2 CXCL8 IL1B IL6 TNF
21
Show member pathways
12.38 CCL5 CXCL8 CXCR1 CXCR2
22
Show member pathways
12.38 CXCL8 IL1B IL6 TLR4 TNF
23
Show member pathways
12.36 ALB CCL2 CCL5 CRP IL1B IL6
24
Show member pathways
12.33 CXCL8 IL10 IL1B IL6 PGF TNF
25
Show member pathways
12.31 CXCL8 IL6 TLR4 TNF
26 12.31 IL10 IL1B IL6 TLR4 TNF
27
Show member pathways
12.3 IL10 IL1B TLR4 TNF
28
Show member pathways
12.29 CCL2 CCL5 CXCL8 CXCR1 CXCR2 IL1B
29
Show member pathways
12.27 CXCL8 IL1B IL6 TNF
30
Show member pathways
12.27 CXCL8 IL1B IL6 TLR4 TNF
31
Show member pathways
12.26 IL10 IL1B IL6 TNF
32 12.26 CXCL8 IL10 IL1B IL6 TNF
33
Show member pathways
12.14 IL10 IL1B IL6 TLR4 TNF
34
Show member pathways
12.14 CCL2 CCL5 CXCL8 IL10 IL1B IL6
35
Show member pathways
12.1 IL1B IL6 TLR4 TNF
36
Show member pathways
12.09 CCL2 CCL5 CXCL8 CXCR1 CXCR2
37 12.08 CCL2 CXCL8 IL1B IL6 TLR4 TNF
38 12.04 CCL2 CCL5 IL1B IL6 TNF
39 12.04 CCL2 CXCL8 IL10 IL1B IL6 TNF
40 12 CCL2 CXCL8 IL1B IL6 TNF
41 11.99 IL10 IL6 TNF
42 11.96 CXCL8 IL1B TLR4 TNF
43 11.95 CXCL8 IL1B IL6
44 11.92 CXCL8 IL10 IL1B IL6 TLR4 TNF
45 11.91 IL1B IL6 TNF
46 11.91 CXCL8 IL1B IL6 TLR4
47
Show member pathways
11.89 CXCL8 IL6 TLR4
48 11.84 IL10 IL1B IL6 TNF
49 11.82 IL10 IL1B TNF
50
Show member pathways
11.76 CXCL8 IL1B IL6 TNF

GO Terms for Pyelonephritis

Cellular components related to Pyelonephritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.7 ACE ALB CCL2 CCL5 CRP CXCL8
2 external side of plasma membrane GO:0009897 9.55 ACE CXCR1 CXCR2 TLR4 TNF
3 extracellular region GO:0005576 9.4 ACE ALB CCL2 CCL5 CRP CXCL8

Biological processes related to Pyelonephritis according to GeneCards Suite gene sharing:

(show top 50) (show all 69)
# Name GO ID Score Top Affiliating Genes
1 regulation of signaling receptor activity GO:0010469 9.97 CCL2 CCL5 CXCL8 IL10 IL1B IL6
2 positive regulation of angiogenesis GO:0045766 9.96 CXCL8 CXCR2 IL1B PGF
3 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.96 IL1B IL6 TLR4 TNF
4 cytokine-mediated signaling pathway GO:0019221 9.95 CCL2 CCL5 CXCL8 IL10 IL1B IL6
5 positive regulation of DNA-binding transcription factor activity GO:0051091 9.92 IL10 IL1B IL6 TNF
6 cellular response to interferon-gamma GO:0071346 9.91 CCL2 CCL5 TLR4
7 defense response to Gram-positive bacterium GO:0050830 9.91 CRP IL6 TNF
8 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.91 CCL2 CCL5 TLR4 TNF
9 chemotaxis GO:0006935 9.91 CCL2 CCL5 CXCL8 CXCR1 CXCR2
10 calcium-mediated signaling GO:0019722 9.9 CXCL8 CXCR1 CXCR2
11 positive regulation of JNK cascade GO:0046330 9.9 IL1B TLR4 TNF
12 cellular response to interleukin-1 GO:0071347 9.9 CCL2 CCL5 CXCL8
13 cell chemotaxis GO:0060326 9.89 CCL2 CCL5 CXCR1 CXCR2
14 regulation of insulin secretion GO:0050796 9.88 CCL5 IL1B TNF
15 positive regulation of T cell proliferation GO:0042102 9.88 CCL5 IL1B IL6
16 humoral immune response GO:0006959 9.87 CCL2 IL6 TNF
17 positive regulation of smooth muscle cell proliferation GO:0048661 9.87 CCL5 IL6 TNF
18 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.86 IL1B TLR4 TNF
19 cellular response to organic cyclic compound GO:0071407 9.86 CCL2 CCL5 IL1B TNF
20 positive regulation of interferon-gamma production GO:0032729 9.85 IL1B TLR4 TNF
21 monocyte chemotaxis GO:0002548 9.85 CCL2 CCL5 IL6
22 positive regulation of nitric oxide biosynthetic process GO:0045429 9.84 IL1B TLR4 TNF
23 receptor internalization GO:0031623 9.84 CXCL8 CXCR1 CXCR2
24 positive regulation of interleukin-6 production GO:0032755 9.84 IL1B IL6 TLR4 TNF
25 chemokine-mediated signaling pathway GO:0070098 9.83 CCL2 CCL5 CXCL8 CXCR1 CXCR2
26 cellular response to fibroblast growth factor stimulus GO:0044344 9.82 CCL2 CCL5 CXCL8
27 negative regulation of interleukin-6 production GO:0032715 9.81 IL10 TLR4 TNF
28 positive regulation of interleukin-8 production GO:0032757 9.8 IL1B TLR4 TNF
29 negative regulation of neurogenesis GO:0050768 9.79 IL1B IL6 TNF
30 protein kinase B signaling GO:0043491 9.78 CCL2 CCL5 IL1B TNF
31 positive regulation of chemokine production GO:0032722 9.77 IL6 TLR4 TNF
32 dendritic cell chemotaxis GO:0002407 9.76 CCL5 CXCR1 CXCR2
33 positive regulation of glial cell proliferation GO:0060252 9.75 IL1B IL6 TNF
34 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.74 IL1B TNF
35 negative regulation of growth of symbiont in host GO:0044130 9.74 IL10 TNF
36 induction of positive chemotaxis GO:0050930 9.74 CXCL8 PGF
37 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.74 CCL2 TLR4
38 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.74 IL10 IL1B TNF
39 macrophage chemotaxis GO:0048246 9.73 CCL2 CCL5
40 negative regulation of G protein-coupled receptor signaling pathway GO:0045744 9.73 CCL5 CXCL8
41 PERK-mediated unfolded protein response GO:0036499 9.73 CCL2 CXCL8
42 response to molecule of bacterial origin GO:0002237 9.73 CXCL8 IL10
43 positive regulation of leukocyte chemotaxis GO:0002690 9.73 CXCR2 IL6
44 neutrophil chemotaxis GO:0030593 9.73 CCL2 CCL5 CXCL8 CXCR1 CXCR2 IL1B
45 positive regulation of interleukin-8 biosynthetic process GO:0045416 9.72 TLR4 TNF
46 endothelial cell apoptotic process GO:0072577 9.72 IL10 TNF
47 response to glucocorticoid GO:0051384 9.72 IL10 IL6 TNF
48 lipopolysaccharide-mediated signaling pathway GO:0031663 9.72 CCL2 CCL5 IL1B TLR4 TNF
49 neutrophil mediated immunity GO:0002446 9.71 ACE IL6
50 positive regulation of chemokine biosynthetic process GO:0045080 9.71 IL1B TNF

Molecular functions related to Pyelonephritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chemokine activity GO:0008009 9.43 CCL2 CCL5 CXCL8
2 C-X-C chemokine receptor activity GO:0016494 9.32 CXCR1 CXCR2
3 cytokine activity GO:0005125 9.17 CCL2 CCL5 CXCL8 IL10 IL1B IL6
4 interleukin-8 binding GO:0019959 9.16 CXCR1 CXCR2
5 interleukin-8 receptor activity GO:0004918 8.96 CXCR1 CXCR2

Sources for Pyelonephritis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....